BRPI0907791A2 - Conjugados rgd-(bacterio)clorofila para terapia fotodinâmica e formação de imagem de tumores necróticos - Google Patents

Conjugados rgd-(bacterio)clorofila para terapia fotodinâmica e formação de imagem de tumores necróticos

Info

Publication number
BRPI0907791A2
BRPI0907791A2 BRPI0907791-0A BRPI0907791A BRPI0907791A2 BR PI0907791 A2 BRPI0907791 A2 BR PI0907791A2 BR PI0907791 A BRPI0907791 A BR PI0907791A BR PI0907791 A2 BRPI0907791 A2 BR PI0907791A2
Authority
BR
Brazil
Prior art keywords
bacterio
rgd
imaging
photodynamic therapy
necrotic tumors
Prior art date
Application number
BRPI0907791-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Avigdor Scherz
Liat Goldshaid
Yoram Salomon
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BRPI0907791A2 publication Critical patent/BRPI0907791A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0451—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
BRPI0907791-0A 2008-02-27 2009-03-01 Conjugados rgd-(bacterio)clorofila para terapia fotodinâmica e formação de imagem de tumores necróticos BRPI0907791A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6429808P 2008-02-27 2008-02-27
PCT/IL2009/000228 WO2009107139A1 (en) 2008-02-27 2009-03-01 Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors

Publications (1)

Publication Number Publication Date
BRPI0907791A2 true BRPI0907791A2 (pt) 2015-08-04

Family

ID=40677556

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907791-0A BRPI0907791A2 (pt) 2008-02-27 2009-03-01 Conjugados rgd-(bacterio)clorofila para terapia fotodinâmica e formação de imagem de tumores necróticos

Country Status (15)

Country Link
US (1) US8815213B2 (enExample)
EP (2) EP2257309B1 (enExample)
JP (1) JP5620279B2 (enExample)
KR (1) KR101595138B1 (enExample)
CN (1) CN102036684B (enExample)
AU (1) AU2009219682B2 (enExample)
BR (1) BRPI0907791A2 (enExample)
CA (1) CA2717060C (enExample)
DK (1) DK2257309T3 (enExample)
ES (1) ES2764781T3 (enExample)
MX (1) MX2010009530A (enExample)
PT (1) PT2257309T (enExample)
RU (1) RU2518296C2 (enExample)
WO (1) WO2009107139A1 (enExample)
ZA (1) ZA201006789B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1968648B1 (en) 2005-12-16 2015-05-06 Catherine M Shachaf Diagnostic system for the detection and diagnosis of skin cancer
US9957293B2 (en) * 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
WO2011020107A2 (en) * 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
KR101253709B1 (ko) * 2011-06-02 2013-04-12 경북대학교 산학협력단 분비형 표적 추적 융합 단백질
AU2012305327B2 (en) 2011-09-05 2016-07-14 Hiroshi Maeda Polymer-type fluorescent molecule probe
CN104303184B (zh) * 2012-03-21 2018-05-15 皇家飞利浦有限公司 整合医疗成像和活检数据的临床工作站以及使用其的方法
CN103705532B (zh) * 2012-10-08 2016-09-14 浙江海正药业股份有限公司 靶向胸苷激酶光敏剂及其药物组合物与治疗癌症的用途
US20150343060A1 (en) 2014-06-02 2015-12-03 Li-Cor, Inc. Treatment of circulating tumor cells using an extracorporeal device
CN111388672A (zh) 2014-08-08 2020-07-10 美国政府(由卫生和人类服务部的部长所代表) 在体内和在体外的靶标的光控移除
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
WO2016090471A1 (en) * 2014-12-08 2016-06-16 University Health Network System and method for enhanced mass spectrometry imaging
JP6793122B2 (ja) * 2014-12-19 2020-12-02 ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． 術中イメージング
TR201810532T4 (tr) * 2015-06-03 2018-08-27 Surgimab S A S Floresan konjügatlar.
AU2016308286B2 (en) 2015-08-18 2022-04-07 Rakuten Medical, Inc. Phthalocyanine dye conjugates and their storage
US11266383B2 (en) 2015-09-22 2022-03-08 University Health Network System and method for optimized mass spectrometry analysis
EP3559019A1 (en) * 2016-12-23 2019-10-30 BicycleTX Limited Peptide ligands for binding to mt1-mmp
JP2020502238A (ja) * 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
WO2019032683A2 (en) * 2017-08-08 2019-02-14 Board Of Trustees Of Michigan State University LIGHT-EMITTING ORGANIC SALTS FOR ENHANCED PHOTODYNAMIC THERAPY AND IMAGING
JP6920931B2 (ja) * 2017-09-01 2021-08-18 富士フイルム株式会社 医療画像処理装置、内視鏡装置、診断支援装置、及び、医療業務支援装置
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
RU2700407C1 (ru) * 2018-07-23 2019-09-16 Михаил Тимофеевич Александров Способ лечения опухолевых и воспалительных заболеваний с применением фотодинамической терапии
CN111171030B (zh) * 2018-11-12 2022-11-22 浙江海正药业股份有限公司 细菌叶绿素衍生物及其制备方法
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4070098B1 (en) * 2019-12-05 2025-12-24 Tempus AI, Inc. Large scale organoid analysis
CN112933252A (zh) * 2021-01-28 2021-06-11 厦门大学附属翔安医院 一种乳腺癌特异靶向分子探针及其制备方法和应用
CN115466311A (zh) * 2021-06-10 2022-12-13 首都医科大学 抗粘附迁移和侵袭的18β-甘草次酸-RGDK,其合成,抗癌转移活性和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121876A1 (de) 1991-07-02 1993-01-14 Scheer Hugo Modifizierte bakteriochlorophylle, verfahren zu ihrer herstellung und ihre verwendung
EP0617705B1 (en) 1991-11-22 1997-09-24 Yeda Research And Development Company, Ltd. Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
IL102645A (en) * 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US6147195A (en) 1993-07-26 2000-11-14 Yeda Research And Development Co., Ltd. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
IL116126A0 (en) 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
JP2001501600A (ja) * 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
DE19756773A1 (de) * 1997-12-19 1999-06-24 Dade Behring Marburg Gmbh Neues Verfahren und Diagnosemittel zur Hämostase-Diagnostik
CA2353554C (en) 1998-12-09 2011-04-26 Yeda Research And Development Co. Ltd. Palladium-substituted bacteriochlorophyll derivatives and use thereof
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
US7045117B2 (en) 1999-12-01 2006-05-16 Yeda Research And Development Co. Ltd. Method for tumor diagnosis comprising administering of palladium-substituted bacteriochlorophyll derivatives
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
EP2322173B1 (en) 2004-06-07 2016-08-10 Yeda Research And Development Co., Ltd. Cationic bacteriochlorophyll derivatives and uses thereof
EP2019667A4 (en) * 2006-04-27 2012-08-22 Barnes Jewish Hospital DETECTION AND IMAGING OF TARGET TISSUE
JP2010502574A (ja) * 2006-08-23 2010-01-28 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Ｒｇｄペプチドとポルフィリン又は（バクテリオ）クロロフィル光合成剤とのコンジュゲート及びその使用
JP2010539163A (ja) * 2007-09-14 2010-12-16 ヘルス リサーチ インコーポレイテッド 腫瘍イメージング及び治療用のマルチモーダル剤

Also Published As

Publication number Publication date
CA2717060A1 (en) 2009-09-03
US8815213B2 (en) 2014-08-26
CN102036684B (zh) 2017-06-09
MX2010009530A (es) 2010-11-30
EP2257309B1 (en) 2019-10-16
AU2009219682B2 (en) 2015-06-18
ZA201006789B (en) 2012-01-25
DK2257309T3 (da) 2020-01-20
CA2717060C (en) 2016-11-01
EP2712627A2 (en) 2014-04-02
KR20100127798A (ko) 2010-12-06
RU2518296C2 (ru) 2014-06-10
US20110064658A1 (en) 2011-03-17
EP2257309A1 (en) 2010-12-08
ES2764781T3 (es) 2020-06-04
AU2009219682A1 (en) 2009-09-03
CN102036684A (zh) 2011-04-27
JP2011513298A (ja) 2011-04-28
WO2009107139A1 (en) 2009-09-03
RU2010139461A (ru) 2012-04-10
EP2712627A3 (en) 2014-04-16
JP5620279B2 (ja) 2014-11-05
KR101595138B1 (ko) 2016-02-18
PT2257309T (pt) 2020-01-22

Similar Documents

Publication Publication Date Title
BRPI0907791A2 (pt) Conjugados rgd-(bacterio)clorofila para terapia fotodinâmica e formação de imagem de tumores necróticos
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0821779A2 (pt) tratamento terapêutico de câncer
DK2121139T3 (da) Formulations for cancer treatment
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
DE602009000539D1 (de) Strahlentherapiegerät
LT3778885T (lt) Dirbtinai sukurtų žmogaus arginazių kompozicijos ir vėžio gydymo metodai
IL216913A0 (en) Targeted nano-photomedicines for photodynamic therapy of cancer
BRPI0922823A2 (pt) Combinações e modos de administração de agentes terapêuticos e terapia de combinação
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI0906389A2 (pt) Sistema de terapia de pele
EP2512512A4 (en) Uniform field magnetization and targeting of therapeutic formulations
IL224370B (en) Combination treatment for prostate carcinoma
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1006438A2 (pt) terapia adjuvante de cancer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0914683A2 (pt) dispositivo para terapia de campo magnético
EP2616065A4 (en) GLYCO-SUBSTITUTED DIHYDROXY-CHLORE AND B-FUNCTIONALIZED CHLORE FOR A PHOTODYNAMIC ANTIMICROBIAL THERAPY
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
PT2632452T (pt) Compostos e composições para o tratamento do cancro
BRPI0922884A2 (pt) compostos para tratamento de câncer
EP3001813A4 (en) Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
EP2340851A4 (en) DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements